Mergers & Acquisitions ·
BioNTech agrees to buy Scholar Rock's PRV for $205M; reports Q3 net loss of $107.2M
SRRKScholar Rock Holding Corp
Scholar Rock Holding Corporation reported a third-quarter 2026 net loss of $107.2 million, or $0.81 per share, on product revenue of $0.6 million from the initial U.S. launch of ISEMBYLD for spinal muscular atrophy. The company also announced that BioNTech US Inc. agreed to purchase its Rare Pediatric Disease Priority Review Voucher for $205 million in cash, subject to customary closing conditions including HSR antitrust review. As of September 30, 2026, Scholar Rock held $413.6 million in cash and marketable securities. The global biopharmaceutical company develops therapies for rare neuromuscular diseases.